Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RAS-F3
- Development stage
- Preclinical
- Lead developer
- Qualigen Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
RAS-F3 is a small molecule **RAS inhibitor** developed by Qualigen Therapeutics. It acts as a protein-protein interaction inhibitor, targeting the RAS oncogene protein by preventing tumor formation through direct inhibition of RAS mutations. RAS-F3 is currently in preclinical development for various cancers, including **colorectal, lung, and pancreatic cancers**.
- Other names
- RAS-FRAS F3
02
Targets
HRAS (H-Ras protein)NRAS (Neuroblastoma RAS viral oncogene homolog)KRAS (Kirsten rat sarcoma viral oncogene homolog)
Beyond the preview
Go deeper on RAS-F3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RAS-F3.